Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDLEY
2019-000201-69Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Nirsevimab with Palivizumab control (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2019; status: completed.
02
Drugs
nirsevimabpalivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-000201-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000201-69.